Ropeginterferon alfa-2B

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 104 publications

Reversible Left Ventricular Dysfunction Related to Ropeginterferon Alfa-2b in Polycythemia Vera.

Reversible Left Ventricular Dysfunction Related to Ropeginterferon Alfa-2b in Polycythemia Vera.

Journal: International heart journal

Published: November 30, 2025

Ropeginterferon alfa-2b in Polycythemia Vera: redefining disease control through molecular targeting.

Ropeginterferon alfa-2b in Polycythemia Vera: redefining disease control through molecular targeting.

Journal: Expert review of anticancer therapy

Published: November 19, 2025

Real-World Retrospective Report on the Efficacy, Tolerability, and Molecular Responses to Ropeginterferon-α2b in Patients with Myeloproliferative Neoplasms.

Real-World Retrospective Report on the Efficacy, Tolerability, and Molecular Responses to Ropeginterferon-α2b in Patients with Myeloproliferative Neoplasms.

Journal: Journal of clinical medicine

Published: November 06, 2025

Effective Treatment with Ruxolitinib and Ropeginterferon Alfa-2b for Refractory TAFRO-like Syndrome.

Effective Treatment with Ruxolitinib and Ropeginterferon Alfa-2b for Refractory TAFRO-like Syndrome.

Journal: Internal medicine (Tokyo, Japan)

Published: October 29, 2025

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Journal: Leukemia

Published: October 28, 2025

Pharmacologic management of ET: established therapies and emerging agents.

Pharmacologic management of ET: established therapies and emerging agents.

Journal: Expert opinion on pharmacotherapy

Published: October 27, 2025

The combination of ropeginterferon alfa-2b with anti-PD1 blockage in adjuvant therapy in HBV-related HCC.

The combination of ropeginterferon alfa-2b with anti-PD1 blockage in adjuvant therapy in HBV-related HCC.

Journal: Hepatology international

Published: October 05, 2025

Towards New Therapy Endpoints in Polycythemia Vera: Targeting Clonal and Inflammatory Pathways.

Towards New Therapy Endpoints in Polycythemia Vera: Targeting Clonal and Inflammatory Pathways.

Journal: Blood advances

Published: August 28, 2025

A new era in the treatment of myeloproliferative neoplasms

A new era in the treatment of myeloproliferative neoplasms

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 06, 2025

A comparative study of hematologic response to ropeginterferon alfa-2b in hydroxyurea-resistant or intolerant polycythemia vera: a real-world data-based analysis.

A comparative study of hematologic response to ropeginterferon alfa-2b in hydroxyurea-resistant or intolerant polycythemia vera: a real-world data-based analysis.

Journal: Blood research

Published: August 03, 2025

Long-term Efficacy and Safety of Ropeginterferon Alfa-2b under its HIDAT Regimen for the Treatment of Polycythemia Vera.

Long-term Efficacy and Safety of Ropeginterferon Alfa-2b under its HIDAT Regimen for the Treatment of Polycythemia Vera.

Journal: Blood advances

Published: August 01, 2025

Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera.

Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera.

Journal: Blood advances

Published: August 01, 2025

Showing 1-12 of 104

Last Updated: 02/24/2026